Omeros Corporation (OMER) |
|
2.875 -0.115 (-3.85%)
|
09-26 15:18 |
|
Open: |
2.99 |
Pre. Close: |
2.99 |
|
High:
|
3.24 |
Low:
|
2.865 |
|
Volume:
|
591,561 |
Market Cap:
|
181(M) |
|
|
|
Technical analysis |
as of: 2023-09-26 2:51:14 PM |
|
Short-term rate:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 4.08 One year: 4.6 |
| Support: |
Support1: 2.77 Support2: 2.31 |
| Resistance: |
Resistance1: 3.49 Resistance2: 3.94 |
| Pivot: |
3.14  |
| Moving Average: |
MA(5): 2.91 MA(20): 3.24
MA(100): 4.84 MA(250): 4.05 |
| MACD: |
MACD(12,26): -0.3  Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 18.9 %D(3): 13.2 |
| RSI: |
RSI(14): 33.9 |
| 52-week: |
High: 7.8 Low: 1.74 |
| Average Vol(K): |
3-Month: 410 (K) 10-Days: 475 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ OMER ] has closed above bottom band by 21.4%. Bollinger Bands are 45.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.99 - 3 |
3 - 3.02 |
|
Low:
|
2.81 - 2.82 |
2.82 - 2.84 |
|
Close:
|
2.97 - 2.99 |
2.99 - 3.01 |
|
Company Description |
|
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington. |
Headline News |
Fri, 22 Sep 2023
Should You Buy Omeros Corp (OMER) in Biotechnology Industry? - InvestorsObserver
Mon, 11 Sep 2023
Do Analysts Agree Monday on Omeros Corp (OMER) Stock's Target Price? - InvestorsObserver
Fri, 01 Sep 2023
How Will the Market React to Omeros Corp (OMER) Stock Getting a Bearish Rating - InvestorsObserver
Wed, 30 Aug 2023
Barclays PLC Grows Stock Holdings in Omeros Co. (NASDAQ:OMER) - MarketBeat
Tue, 15 Aug 2023
Institutions own 40% of Omeros Corporation (NASDAQ:OMER) shares but individual investors control 56% of the company - Yahoo Finance
Wed, 09 Aug 2023
Omeros: Q2 Earnings Snapshot - The Seattle Times
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
63 (M) |
| Shares Float |
60 (M) |
|
% Held by Insiders
|
4 (%) |
|
% Held by Institutions
|
33.8 (%) |
|
Shares Short
|
12,110 (K) |
|
Shares Short P.Month
|
11,370 (K) |
Stock Financials |
|
EPS
|
-2.82 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.33 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-24 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-2.65 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
90 (M) |
|
Levered Free Cash Flow
|
-81 (M) |
Stock Valuations |
|
PE Ratio
|
-1.04 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
8.81 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
2.02 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
